Insulet has reinstated its chief commercial officer role after eliminating it three years ago.
The Acton-based medical device manufacturer appointed Mike Panos to the resurrected position.
Panos assumed his role as executive vice president, CCO of Insulet on Monday. In his new role, he will oversee the company’s global commercial operations, including developing commercial strategies, growing market access, and supporting future growth, the company announced.
Insulet develops and produces Omnipod, a line of tubeless insulin pumps for people with type 1 and type 2 diabetes. Panos’ hiring comes as the company is implementing new strategies to strengthen its capabilities, said Insulet President and CEO Ashley McEvoy.
Panos joins Insulet after working for three decades at Stryker, a Michigan-based medical device and equipment manufacturer. Panos began his tenure with the firm as a marketing associate in 1996, and most recently served as its leader, sales excellence, according to his LinkedIn profile.
Panos graduated with his bachelor’s and master’s degrees from Boston College.
Insulet originally eliminated its CCO position as part of an overall executive restructuring when Bret Christensen left the role to pursue another opportunity on May 5, 2023.
Christensen’s responsibilities were then split between Insulet’s international general manager and U.S. general manager. As part of the reorganization, Insulet created a chief technology officer position and its first chief product and customer experience officer position.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
